Onkologie. 2024:18(1):18-21 | DOI: 10.36290/xon.2024.004

News in the systemic treatment of endometrial cancer

Denisa Pohanková1, Veronika Novotná1, Munachiso Ndukwe2
1 Klinika onkologie a radioterapie, Fakultní nemocnice Hradec Králové
2 Porodnická a gynekologická klinika, Fakultní nemocnice Hradec Králové

Endometrial tumours (EC) are a disease with an increasing incidence. Currently they are the sixth most common cancer in women worldwide. EC include several histological subtypes with different prognoses. Currently, the molecular classification of the tumour is gaining importance, which can significantly influence the planned treatment procedure and leads to the possibility of using precisely targeted individualized treatment for each patient.

Keywords: endometrial tumours, adjuvant therapy, gynecological malignancies.

Accepted: February 22, 2024; Published: February 28, 2024  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Pohanková D, Novotná V, Ndukwe M. News in the systemic treatment of endometrial cancer. Onkologie. 2024;18(1):18-21. doi: 10.36290/xon.2024.004.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Makker V, MacKay H, Ray-Coquard I, et al. Endometrial cancer. Nat Rev Dis Primer. 2021;7(1):88. Go to original source... Go to PubMed...
    2. Available from: https://www.wcrf.org/cancer-trends/endometrial-cancer-statistics/.
    3. Henley SJ, Ward EM, Scott S, et al. Annual report to the nation on the status of cancer, part I: National cancer statistics. Cancer. 2020;126(10):2225-2249. Go to original source... Go to PubMed...
    4. Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021;71(3):209-249. Go to original source... Go to PubMed...
    5. Available from: https://www.svod.cz. [cited 10.10.2023].
    6. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018: Cancer Statistics, 2018. CA Cancer J Clin. 2018;68(1):7-30. Go to original source... Go to PubMed...
    7. Burke WM, Orr J, Leitao M, et al. Endometrial cancer: a review and current management strategies: Part I. Gynecol Oncol. 2014;134(2):385-392. Go to original source... Go to PubMed...
    8. McDonald ME, Bender DP. Endometrial Cancer. Obstet Gynecol Clin North Am. 2019;46(1):89-105. Go to original source... Go to PubMed...
    9. Liao C, Zhang D, Mungo C, et al. Is diabetes mellitus associated with increased incidence and disease-specific mortality in endometrial cancer? A systematic review and meta-analysis of cohort studies. Gynecol Oncol. 2014;135(1): 163-171.Další literatura u autorky a na www.onkologiecs.cz Go to original source... Go to PubMed...
    10. Esposito G, Bravi F, Serraino D, et al. Diabetes Risk Reduction Diet and Endometrial Cancer Risk. Nutrients. 2021;13(8):2630. Go to original source... Go to PubMed...
    11. Perez-Lopez FR, Pasupuleti V, Gianuzzi X, et al. Systematic review and meta-analysis of the effect of metformin treatment on overall mortality rates in women with endometrial cancer and type 2 diabetes mellitus. Maturitas. 2017;101:6-11. Go to original source... Go to PubMed...
    12. Pérez-Martín AR, Castro-Eguiluz D, Cetina-Pérez L, et al. Impact of metabolic syndrome on the risk of endometrial cancer and the role of lifestyle in prevention. Bosn J Basic Med Sci [Internet]. 2022 Feb 27 [cited 2023 Jul 18]. Available from: https://www.bjbms.org/ojs/index.php/bjbms/article/view/6963. Go to original source... Go to PubMed...
    13. Bats AS, Rossi L, Le Frere-Belda MA, et al. Syndrome de Lynch et cancer de l'endomètre. Bull Cancer (Paris). 2017;104(12):1013-1021. Go to original source... Go to PubMed...
    14. Zhao S, Chen L, Zang Y, et al. Endometrial cancer in Lynch syndrome. Int J Cancer. 2022;150(1):7-17. Go to original source... Go to PubMed...
    15. Brooks RA, Fleming GF, Lastra RR, et al. Current recommendations and recent progress in endometrial cancer. CA Cancer J Clin. 2019;caac.21561. Go to original source... Go to PubMed...
    16. Farooq A, Walker LJ, Bowling J, et al. Cowden syndrome. Cancer Treat Rev. 2010;36(8):577-583. Go to original source... Go to PubMed...
    17. Shai A, Segev Y, Narod SA. Genetics of endometrial cancer. Fam Cancer. 2014;13(3):499-505. Go to original source... Go to PubMed...
    18. Faria SC, Devine CE, Rao B, et al. Imaging and Staging of Endometrial Cancer. Semin Ultrasound CT MRI. 2019;40(4): 287-294. Go to original source... Go to PubMed...
    19. Sbarra M, Lupinelli M, Brook OR, et al. Imaging of Endometrial Cancer. Radiol Clin North Am. 2023;61(4):609-625. Go to original source... Go to PubMed...
    20. Akin EA, Kuhl ES, Zeman RK. The role of FDG-PET/CT in gynecologic imaging: an updated guide to interpretation and challenges. Abdom Radiol. 2018;43(9):2474-2486. Go to original source... Go to PubMed...
    21. Van Den Heerik ASVM, Horeweg N, De Boer SM, et al. Adjuvant therapy for endometrial cancer in the era of molecular classification: radiotherapy, chemoradiation and novel targets for therapy. Int J Gynecol Cancer. 2021;31(4):594-604. Go to original source... Go to PubMed...
    22. Imboden S, Nastic D, Ghaderi M, et al. Phenotype of POLE-mutated endometrial cancer. PLOS ONE. 2019;14(3):e0214318. Go to original source... Go to PubMed...
    23. Dundr P, Cibula D, Doležel M, et al. Molekulární testování u karcinomu endometria- společné doporučení České onkologické společnosti, onkogynekologické sekce České gynekologické a porodnické společnosti, Společnosti radiační onkologie, biologie a fyziky a Společnosti českých patologů. Klin Onkol. 2021;34(4):321-328.
    24. Gien L, Kwon J, Oliver TK, et al. Adjuvant Hormonal Therapy for Stage I Endometrial Cancer. Curr Oncol. 2008;15(3): 126-135. Go to original source... Go to PubMed...
    25. MacKay HJ, Freixinos VR, Fleming GF. Therapeutic Targets and Opportunities in Endometrial Cancer: Update on Endocrine Therapy and Nonimmunotherapy Targeted Options. Am Soc Clin Oncol Educ Book. 2020;(40):245-255. Go to original source... Go to PubMed...
    26. Green AK, Feinberg J, Makker V. A Review of Immune Checkpoint Blockade Therapy in Endometrial Cancer. Am Soc Clin Oncol Educ Book. 2020;(40):238-244. Go to original source... Go to PubMed...
    27. Johnson N, Cornes P. Survival and recurrent disease after postoperative radiotherapy for early endometrial cancer: systematic review and meta-analysis. BJOG Int J Obstet Gynaecol. 2007;114(11):1313-1320. Go to original source... Go to PubMed...
    28. Van Den Heerik ASVM, Horeweg N, Nout RA, et al. PORTEC-4a: international randomized trial of molecular profile-based adjuvant treatment for women with high-intermediate risk endometrial cancer. Int J Gynecol Cancer. 2020;30(12):2002-2007. Go to original source... Go to PubMed...
    29. Nasioudis D, Oh J, Ko EM, et al. Adjuvant chemotherapy for stage I high-intermediate risk endometrial carcinoma with lymph-vascular invasion. Int J Gynecol Cancer. 2022;32(9):1129-1134. Go to original source... Go to PubMed...
    30. Creutzberg CL, Nout RA, Lybeert MLM, et al. Fifteen-Year Radiotherapy Outcomes of the Randomized PORTEC-1 Trial for Endometrial Carcinoma. Int J Radiat Oncol. 2011;81(4):e631-638. Go to original source... Go to PubMed...
    31. De Boer SM, Powell ME, Mileshkin L, et al. Adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): final results of an international, open-label, multicentre, randomised, phase 3 trial. Lancet Oncol. 2018;19(3):295-309. Go to original source... Go to PubMed...
    32. Randall ME, Filiaci VL, Muss H, et al. Randomized Phase III Trial of Whole-Abdominal Irradiation Versus Doxorubicin and Cisplatin Chemotherapy in Advanced Endometrial Carcinoma: A Gynecologic Oncology Group Study. J Clin Oncol. 2006;24(1):36-44. Go to original source... Go to PubMed...
    33. León-Castillo A, De Boer SM, Powell ME, et al. Molecular Classification of the PORTEC-3 Trial for High-Risk Endometrial Cancer: Impact on Prognosis and Benefit From Adjuvant Therapy. J Clin Oncol. 2020;38(29):3388-3397. Go to original source... Go to PubMed...
    34. Mao W, Wei S, Yang H, et al. Clinicopathological study of organ metastasis in endometrial cancer. Future Oncol. 2020;16(10):525-540. Go to original source... Go to PubMed...
    35. Kurra V, Krajewski KM, Jagannathan J, et al. Typical and atypical metastatic sites of recurrent endometrial carcinoma. Cancer Imaging. 2013;13(1):113-122. Go to original source... Go to PubMed...
    36. Nagao S, Nishio S, Okada S, et al. What is an appropriate second-line regimen for recurrent endometrial cancer? Ancillary analysis of the SGSG012/GOTIC004/Intergroup study. Cancer Chemother Pharmacol. 2015;76(2):335-342. Go to original source... Go to PubMed...
    37. Matoda M, Omatsu K, Yamamoto A, et al. Importance of platinum-free interval in second-line chemotherapy for advanced or recurrent endometrial cancer. Eur J Gynaecol Oncol. 2014;35(3):224-229.
    38. Kailasam A, Langstraat C. Contemporary Use of Hormonal Therapy in Endometrial Cancer: a Literature Review. Curr Treat Options Oncol. 2022;23(12):1818-1828. Go to original source... Go to PubMed...
    39. Ethier JL, Desautels DN, Amir E, et al. H. Is hormonal therapy effective in advanced endometrial cancer? A systematic review and meta-analysis. Gynecol Oncol. 2017;147(1):158-166. Go to original source... Go to PubMed...
    40. Available from: https://www.linkos.cz/lekar-a-multidisciplinarni-tym/personalizovana-onkologie/modra-kniha-cos/aktualni-vydani-modre-knihy/29-16-zhoubny-novotvar-tela-delozniho-c54/ [cited 2.12.2023].
    41. Marabelle A, Le DT, Ascierto PA, et al. Efficacy of Pembrolizumab in Patients With Noncolorectal High Microsatellite Instability/Mismatch Repair-Deficient Cancer: Results From the Phase II KEYNOTE-158 Study. J Clin Oncol. 2020;38(1):1-10. Go to original source... Go to PubMed...
    42. Marth C, Tarnawski R, Tyulyandina A, et al. Phase 3, randomized, open-label study of pembrolizumab plus lenvatinib versus chemotherapy for first-line treatment of advanced or recurrent endometrial cancer: ENGOT-en9/LEAP-001. Int J Gynecol Cancer. 2022;32(1):93-100. Go to original source... Go to PubMed...
    43. Makker V, Taylor MH, Aghajanian C, et al. Lenvatinib Plus Pembrolizumab in Patients With Advanced Endometrial Cancer. J Clin Oncol. 2020;38(26):2981-2992. Go to original source... Go to PubMed...
    44. Oaknin A, Ellard SL, Leath Iii C, et al. Preliminary safety, efficacy, and PK/PD characterization from GARNET, a phase I clinical trial of the anti-PD-1 monoclonal antibody, TSR-042, in patients with recurrent or advanced MSI-H endometrial cancer. Ann Oncol. 2018;29:viii334. Go to original source...
    45. Shisler R, Sinnott JA, Wang V, et al. Life after endometrial cancer: A systematic review of patient-reported outcomes. Gynecol Oncol. 2018;148(2):403-413. Go to original source... Go to PubMed...

    Return to the content


    Oncology

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.